Dr. Steve S Um, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 105 Nason Dr, Roaring Spring, PA 16673 Phone: 814-224-2141 Fax: 814-224-6247 |
Ovais Maqbool, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 105 Nason Dr, Roaring Spring, PA 16673 Phone: 814-224-6271 |
News Archive
Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
HelloMD today announced the release of its Telehealth services for patients everywhere, to access some of the world's leading medical specialists. Top doctors from the west coast continue adding to the list of medical specialists available on the site.
Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2009.
› Verified 6 days ago